Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Cagrilintide vs Semaglutide
An educational, source-based comparison of Cagrilintide and Semaglutide — how each peptide works, what it's researched for, and what to know before going deeper.
A long-acting analog of amylin, a pancreatic hormone co-secreted with insulin. It slows gastric emptying, increases satiety, and suppresses glucagon — complementary to GLP-1 mechanisms.
- Weight management as monotherapy and combined with semaglutide (CagriSema)
- Glycemic control in type 2 diabetes
- • Investigational; not yet FDA-approved as monotherapy.
- • GI side effects similar to GLP-1 agonists.
A long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central GLP-1 receptors.
- Type 2 diabetes (Ozempic, Rybelsus)
- Obesity / chronic weight management (Wegovy)
- Cardiovascular risk reduction (SELECT trial)
- • FDA-approved with established safety profile but real side effects (GI, pancreatitis risk, gallbladder events).
- • Requires physician oversight and prescription.
- • Compounded versions vary in quality.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Cagrilintide | Cagrilintide plus semaglutide for obesity (Phase 2) | The Lancet | 2021 | Combination produced greater weight loss than either agent alone. |
| Semaglutide | Semaglutide for weight loss in adults with overweight or obesity (STEP 1) | New England Journal of Medicine | 2021 | Mean ~15% weight loss at 68 weeks versus placebo. |
| Semaglutide | Cardiovascular outcomes with semaglutide (SELECT) | New England Journal of Medicine | 2023 | Reduced MACE in adults with CVD and overweight/obesity. |
Side-effect & safety grid
- Investigational; not yet FDA-approved as monotherapy.
- GI side effects similar to GLP-1 agonists.
- FDA-approved with established safety profile but real side effects (GI, pancreatitis risk, gallbladder events).
- Requires physician oversight and prescription.
- Compounded versions vary in quality.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Cagrilintide vs Semaglutide — Key differences
- Class: Cagrilintide is classified as Metabolic · Amylin, while Semaglutide is Metabolic · Incretin.
- Primary research focus: Cagrilintide — weight management as monotherapy and combined with semaglutide (cagrisema); Semaglutide — type 2 diabetes (ozempic, rybelsus).
- Tag: Weight loss vs Weight loss.
Semaglutide Research Protocol Table
Structured summary of dosing, routes, and durations as described in published research and FDA labels. Educational reference only — not dosing guidance.
| Context | Population | Route | Dose | Duration | Notes |
|---|---|---|---|---|---|
| Type 2 diabetes (FDA-approved, Ozempic) | Adults with type 2 diabetes | Once-weekly subcutaneous injection | 0.25 mg starter for 4 weeks, then 0.5 mg; may increase to 1 mg and 2 mg | Ongoing, prescriber-directed | Starter dose is for tolerability, not glycemic effect. Reflects approved prescribing information. |
| Chronic weight management (FDA-approved, Wegovy) | Adults with obesity or overweight plus a weight-related condition | Once-weekly subcutaneous injection | Escalated monthly: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg maintenance | 68-week trial programme; ongoing in practice | STEP-1 reported ~14.9% mean weight reduction at 68 weeks versus ~2.4% with placebo. |
| Oral formulation (Rybelsus) | Adults with type 2 diabetes | Oral tablet, once daily, fasted with ≤120 mL water | 3 mg for 30 days, then 7 mg, optionally 14 mg | Ongoing | Absorption depends on the SNAC carrier and strict fasting conditions. |
Semaglutide — Frequently Asked Questions
What is semaglutide in one sentence?+
Semaglutide is an FDA-approved GLP-1 receptor agonist prescribed for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy), given as a once-weekly injection or a daily tablet.
How much weight loss did semaglutide produce in trials?+
In the STEP-1 trial, adults without diabetes taking semaglutide 2.4 mg weekly lost about 14.9% of body weight at 68 weeks versus about 2.4% on placebo. Results in people with type 2 diabetes (STEP-2) were smaller, near 9.6%.
How does semaglutide work?+
It mimics GLP-1, increasing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite circuits to reduce energy intake.
What are the most common semaglutide side effects?+
Nausea, vomiting, diarrhea, and constipation are the most frequently reported and are usually dose-related and managed with slow titration. Labeling also carries a boxed warning about thyroid C-cell tumors observed in rodents.
Is compounded semaglutide the same as Ozempic or Wegovy?+
No. Compounded preparations are not FDA-evaluated for safety, efficacy, or quality, and the FDA has warned about dosing errors and unapproved salt forms such as semaglutide sodium and semaglutide acetate.
Semaglutide vs tirzepatide — which is stronger?+
In SURMOUNT-5, the one head-to-head trial in adults with obesity and without diabetes, tirzepatide produced roughly 20% mean weight reduction at 72 weeks versus roughly 14% for semaglutide. Both are prescription-only and titrated under clinical supervision.